Costs and return to scale analysis of extending the offer of pre-exposure prophylaxis (PrEP) to key populations aged 15–17 years old in two Brazilian cities
PLOS One · 08.10.2025 · 20 (10) · e0332901
DOI: 10.1371/journal.pone.0332901 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS One, online erschienen am 08.10.2025. Verfasst von Andreia Costa Santos und 6 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Sports, Technology and Health Sciences, St Mary's University, London, United Kingdom. Hauptthemen laut MEDLINE: Pre-Exposure Prophylaxis, HIV Infections, Anti-HIV Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: UNITAID.
Abstract (Originalsprache)
In Brazil, HIV infection incidence is increasing, particularly among men who have sex with men (MSM) and transgender women (TGW). Pre-exposure prophylaxis (PrEP) is an effective prevention strategy, offered for free for those 15 years and over, in the Brazilian National Health System (SUS), but without a consistent demand creation strategy (DCS) to support the Sustainable Development Goals targets. The objectives of this study are to assess (1) the total incremental cost, and average total incremental costs of PrEP delivery, including DCS, targeting MSM and TGW adolescent aged 15–17 years old, and (2) the potential gains of scale for the expansion of PrEP at SUS, based on different scenarios to reach the UNAIDS goals for HIV targets. We estimated the total incremental and average total incremental cost, and the gains of scale for the expansion of PrEP delivery in SUS using Cobb-Douglas functions. The average total incremental cost per PrEP delivery was estimated at USD 321 in Salvador and USD 254 in São Paulo. Gains of scale were observed in both study settings and nationally for the Brazilian SUS. Our estimates show that investments in expanding PrEP delivery to 15–17 years old will likely reduce average total incremental costs to the Brazilian SUS. However, a cost-effectiveness analysis would be required to assess whether investments in an expansion of PrEP delivery would maximise the benefits of reducing the incidence of HIV/AIDS among the target population compared to the current Brazilian SUS practices.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Faculty of Sports, Technology and Health Sciences, St Mary's University, London, United Kingdom.
- Instituto de Saúde Coletiva, Universidade Federal da Bahia, Salvador, Brazil.
- Escola Politécnica, Universidade Federal da Bahia, Salvador, Brazil.
- Departamento de Medicina Preventiva, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil.
- Departamento de Ciências da Vida, Universidade do Estado da Bahia, Salvador, Brazil.
ORCID-Profile: Andreia Costa Santos, Joilson Nascimento Paim, Patricia Coelho de Soarez
Förderung
- UNITAID
Zitieren
APA
Costa Santos, A., Paim, J. N., de Soarez, P. C., Cerchiari, N., Magno, L., Dourado, I., & Grangeiro, A. (2025). Costs and return to scale analysis of extending the offer of pre-exposure prophylaxis (PrEP) to key populations aged 15–17 years old in two Brazilian cities. PLOS One, 20(10), e0332901. https://doi.org/10.1371/journal.pone.0332901
Vancouver
Costa Santos A, Paim JN, de Soarez PC, Cerchiari N, Magno L, Dourado I, et al. Costs and return to scale analysis of extending the offer of pre-exposure prophylaxis (PrEP) to key populations aged 15–17 years old in two Brazilian cities. PLOS One. 2025;20(10):e0332901. doi:10.1371/journal.pone.0332901
BibTeX
@article{CostaSantos2025,
author = {Costa Santos, Andreia and Paim, Joilson Nascimento and de Soarez, Patricia Coelho and Cerchiari, Natacha and Magno, Laio and Dourado, Ines and Grangeiro, Alexandre},
title = {Costs and return to scale analysis of extending the offer of pre-exposure prophylaxis (PrEP) to key populations aged 15–17 years old in two Brazilian cities},
journal = {PLOS One},
year = {2025},
volume = {20},
number = {10},
pages = {e0332901},
doi = {10.1371/journal.pone.0332901}
}
EUVIMED